These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28482804)

  • 21. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
    Anderson JA; Hirsh J; Yusuf S; Johnston M; Afzal R; Mehta SR; Fox KA; Budaj A; Eikelboom JW
    J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience.
    Schiele F; Meneveau N; Seronde MF; Descotes-Genon V; Dutheil J; Chopard R; Ecarnot F; Bassand JP;
    Am Heart J; 2010 Feb; 159(2):190-8. PubMed ID: 20152216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
    Blick SK; Orman JS; Wagstaff AJ; Scott LJ
    Am J Cardiovasc Drugs; 2008; 8(2):113-25. PubMed ID: 18422394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome.
    Rosenthal N; Xiao Z; Kartashov A; Levorsen A; Shah BR
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):93-101. PubMed ID: 32578166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes.
    Yan HB; Song L; Liu R; Zhao HJ; Wang SP; Chi YP; Zheng B; Li WZ; Liu C; Zhou P
    Chin Med J (Engl); 2011 Mar; 124(6):879-86. PubMed ID: 21518596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fondaparinux versus enoxaprin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis.
    Kossovsky M; Keller PF; Mach F; Gaspoz JM
    Swiss Med Wkly; 2012; 142():w13536. PubMed ID: 22430741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome.
    Latour-Perez J; de-Miguel-Balsa E
    Pharmacoeconomics; 2009; 27(7):585-95. PubMed ID: 19663529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery.
    Landenhed M; Johansson M; Erlinge D; Olsson ML; Bjursten H
    Scand Cardiovasc J; 2010 Apr; 44(2):100-6. PubMed ID: 19961287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fondaparinux versus enoxaparin in the contemporary management of non-ST-elevation acute coronary syndromes. Insights from a multicenter registry.
    Almendro-Delia M; Izquierdo-Bajo Á; Madrona-Jiménez L; Blanco-Ponce E; Seoane-García T; García-Del Río M; Carmona-Carmona J; Arboleda Sánchez JA; Rodríguez Yáñez JC; Soto Blanco JM; Fernández García I; Castillo Caballero JA; Hidalgo-Urbano RJ; García-Rubira JC
    Int J Cardiol; 2021 Jun; 332():29-34. PubMed ID: 33667576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
    ; Mehta SR; Yusuf S; Granger CB; Wallentin L; Peters RJ; Bassand JP; Budaj A; Joyner C; Chrolavicius S; Fox KA
    Am Heart J; 2005 Dec; 150(6):1107. PubMed ID: 16338245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.
    Simoons ML; Bobbink IW; Boland J; Gardien M; Klootwijk P; Lensing AW; Ruzyllo W; Umans VA; Vahanian A; Van De Werf F; Zeymer U;
    J Am Coll Cardiol; 2004 Jun; 43(12):2183-90. PubMed ID: 15193678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fondaparinux: an overview.
    Nadar SK; Goyal D; Shantsila E; Banerjee P; Lip GY
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):577-85. PubMed ID: 19505272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: 1-year outcomes of the ProAcor Study.
    Goss F; Brachmann J; Hamm CW; Haerer W; Reifart N; Levenson B
    Vasc Health Risk Manag; 2017; 13():127-137. PubMed ID: 28435280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
    Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
    J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
    Davidson BL; Büller HR; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob GE; Segers AE; Lensing AW;
    J Thromb Haemost; 2007 Jun; 5(6):1191-4. PubMed ID: 17403087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Parenteral Anticoagulation Therapy With Outcomes in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Without Invasive Therapy: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project.
    Liu YH; Fan HL; Zeng LH; Duan CY; Chen G; Chen PY; Zhao D; Liu J; Hao YC; He WF; Tao S; Wei XB; Jiang L; Guo W; Guo YS; Chen W; Li J; Hu YZ; Li WS; Chen YY; Luo JF; Zhou YL; Yu DQ; Han YL; Tan N; Chen JY; He PC
    Clin Pharmacol Ther; 2021 Oct; 110(4):1119-1126. PubMed ID: 34287856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
    Mahaffey KW; Tonev ST; Spinler SA; Levine GN; Gallo R; Ducas J; Goodman SG; Antman EM; Becker RC; Langer A; White HD; Aylward PE; Col JJ; Ferguson JJ; Califf RM;
    Int J Cardiol; 2010 Mar; 139(2):123-33. PubMed ID: 19012977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
    Yoshida Rde A; Yoshida WB; Maffei FH; El Dib R; Nunes R; Rollo HA
    Ann Vasc Surg; 2013 Apr; 27(3):355-69. PubMed ID: 23351997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.